检索结果-南通市图书馆

Targeted therapies in gastric cancer and future perspectives

World Journal of Gastroenterology 2016年第2期22卷 471-489页

作者： Ozan Yazici M Ali Nahit Sendur nuriye ozdemir Sercan Aksoy Department of Medical Oncology Ankara Numune Education and Research HospitalAnkara 06100Turkey Department of Medical Oncology Yildirim Beyazit UniversityAnkara 06100Turkey Department of Medical Oncology Hacettepe University Cancer InstituteAnkara 06100Turkey

Advanced gastric cancer(AGC) is associated with a high mortality rate and, despite multiple new chemotherapy options, the survival rates of patients with AGC remains poor. After the discovery of targeted therapies, research has focused on the new treatment options for AGC. In the last two decades, many targeted molecules were developed against AGC. Currently, two targeted therapy molecules have been approved for patients with AGC. In 2010, trastuzumab was the first molecule shown to improve survival in patients with HER2-positive AGC as part of a first-line combination regimen. In 2014, ramucirumab was the second targeted molecule to improve survival rates and was suggested as treatment for patients with AGC who had progressed after firstline platinum plus fluoropyrimidine with or without anthracycline chemotherapy. Ramucirumab was the first targeted therapy acting as a single agent in patients with advanced gastroesophageal cancers. Although these two molecules were introduced into clinical use, many other promising molecules have been tested in phase Ⅰ-Ⅱ trials. It is obvious that in the near future many different targeted therapies will be in use for treatment of AGC. In this review, the current status of targeted therapies in the treatment of AGC and gastroesophageal junction tumors, including HER(2-3) inhibitors, epidermal growth factor receptor inhibitors, tyrosine kinase inhibitors, antiangiogenic agents, c-MET inhibitors, mammalian target of rapamycin inhibitors, agents against other molecular pathways fibroblast growth factor, Claudins, insulin-like growth factor, heat shock proteins, and immunotherapy, will be discussed.

关键词： Targeted therapies Antibodies Gastriccancer Tyrosine kinase Survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma

引用

Chinese Journal of Cancer Research 2015年第4期27卷 408-416页

作者： Nedim Turan Mustafa Benekli Olcun Umit Unal ?lkay Tugba Unek Didem Tastekin Faysal Dane Efnan Alg?n Sukran Ulger Tulay Eren Turkan Ozturk Topcu Esma Turkmen Nalan Akgül Babacan Gulnihal Tufan Zuhat Urakci Basak Oven Ustaalioglu Ozlem Sonmez Uysal Ozlem Balvan Ercelep Burcu Yapar Taskoylu Asude Aksoy Mustafa Canhoroz Umut Demirci Erkan Dogan Veli Berk Ozan Balakan Ahmet ?iyar Ekinci Mukremin Uysal ?brahim Petekkaya Sel?uk Cemil Ozturk ?nder Tonyal? Bülent ?etin Mehmet Naci Aldemir Kaan Helvac? nuriye ozdemir ?lhan Oztop Ugur Coskun Aytug Uner Ahmet Ozet Suleyman Buyukberber Department of Medical Oncology Faculty of Medicine Cumhuriyet University Department of Medical Oncology Faculty of Medicine Gazi University Department of Medical Oncology Faculty of Medicine Dokuz Eylul University Department of Medical Oncology Faculty of Medicine Necmettin Erbakan University Department of Medical Oncology Faculty of Medicine Marmara University Department of Radiation Oncology Faculty of Medicine Gazi University Department of Medical Oncology Numune Education and Research Hospital Department of Medical Oncology Faculty of Medicine Karadeniz Technical University Department of Medical Oncology Faculty of Medicine Trakya University Department of Medical Oncology Rize Education and Research Hospital Department of Medical Oncology Faculty of Medicine Dicle University Department of Medical Oncology Dr.Lutfi Kirdar Kartal Education and Research Hospital Department of Medical Oncology Sakarya Education and Research Hospital Department of Medical Oncology Faculty of Medicine Pamukkale University Department of Medical Oncology Faculty of Medicine Inonu University Department of Medical Oncology Faculty of Medicine Firat University Department of Medical Oncology Dr.Abdurrahman Yurtaslan Education and Research Hospital Department of Medical Oncology Faculty of Medicine Yuzuncu Yil University Department of Medical Oncology Faculty of Medicine Erciyes University Department of Medical Oncology Faculty of Medicine Sutcu Imam University Department of Medical Oncology Diyarbakir Education and Research Hospital Department of Medical Oncology Faculty of Medicine Kocatepe University Department of Medical Oncology Dr.Ersin Arslan State Hospital Department of Medical Oncology Education and Research Hospital Ad?yaman University Department of Medical Oncology Faculty of Medicine Mustafa Kemal University Department of Medical Oncology Faculty of Medicine Ataturk University

Background： We examined the impact of adjuvant modalities on resected pancreatic and periampullary adenocarcinoma（PAC）.Methods： A total of 563 patients who were curatively resected for PAC were retrospectively analyzed between 2003 and ***： Of 563 patients, 472 received adjuvant chemotherapy（CT） alone, chemoradiotherapy（CRT） alone, and chemoradiotherapy plus chemotherapy（CRT-CT） were analyzed. Of the 472 patients, 231 were given CRT-CT, 26 were given CRT, and 215 were given CT. The median recurrence-free survival（RFS） and overall survival（OS） were 12 and 19 months, respectively. When CT and CRT-CT groups were compared, there was no significant difference with respect to both RFS and OS, and also there was no difference in RFS and OS among CRT-CT, CT and CRT groups. To further investigate the impact of radiation on subgroups, patients were stratified according to lymph node status and resection margins. In node-positive patients, both RFS and OS were significantly longer in CRT-CT than CT. In contrast, there was no significant differencebetween groups when patients with node-negative disease or patients with or without positive surgical margins were ***： Addition of radiation to CT has a survival benefit in patients with node-positive disease following pancreatic resection.

关键词： Pancreatic adenocarcinoma adjuvant chemotherapy(adjuvant CT) adjuvant radiotherapy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：